ECSP024365A - Moleculas mutantes solubles ctla4 y sus aplicaciones - Google Patents

Moleculas mutantes solubles ctla4 y sus aplicaciones

Info

Publication number
ECSP024365A
ECSP024365A EC2002004365A ECSP024365A ECSP024365A EC SP024365 A ECSP024365 A EC SP024365A EC 2002004365 A EC2002004365 A EC 2002004365A EC SP024365 A ECSP024365 A EC SP024365A EC SP024365 A ECSP024365 A EC SP024365A
Authority
EC
Ecuador
Prior art keywords
ctla4
mutant molecules
applications
amino acid
molecules
Prior art date
Application number
EC2002004365A
Other languages
English (en)
Inventor
Juergen Bajorath
Robert J Peach
Joseph R Naemura
Peter S Linsley
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of ECSP024365A publication Critical patent/ECSP024365A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención ofrece las moléculas mutantes CTLA4 solubles que se ligan con mayor intensidad a los antígenos CD80 y/o CD86 que a los CTLA4 de tipo agresivo o CTLA4 Ig no mutados. Las moléculas CTLA4 solubles tienen una primera secuencia de aminoácido conteniendo el dominio extracelular de CTLA4, donde ciertos residuos de aminoácidos son mutados en las regiones 825- R33 Y M97-G107. Las molécular mutantes de la invención pueden también incluir una segunda secuencia de aminoácidos que aumentan la solubilidad de las moléculas mutantes.
EC2002004365A 2000-05-26 2002-11-26 Moleculas mutantes solubles ctla4 y sus aplicaciones ECSP024365A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57992700A 2000-05-26 2000-05-26
US21406500P 2000-06-26 2000-06-26

Publications (1)

Publication Number Publication Date
ECSP024365A true ECSP024365A (es) 2003-03-31

Family

ID=26908652

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2002004365A ECSP024365A (es) 2000-05-26 2002-11-26 Moleculas mutantes solubles ctla4 y sus aplicaciones

Country Status (41)

Country Link
EP (3) EP1536234B1 (es)
JP (1) JP4328525B2 (es)
KR (2) KR100889887B1 (es)
CN (2) CN101255192A (es)
AR (1) AR031699A1 (es)
AT (1) ATE271066T1 (es)
AU (2) AU6346601A (es)
BE (1) BE2011C041I2 (es)
BR (1) BRPI0111191B8 (es)
CA (1) CA2409748C (es)
CY (2) CY2011019I2 (es)
CZ (1) CZ304451B6 (es)
DE (2) DE60104282T2 (es)
DK (1) DK1248802T3 (es)
EC (1) ECSP024365A (es)
EE (2) EE05458B1 (es)
EG (1) EG24459A (es)
ES (2) ES2225549T3 (es)
FR (1) FR11C0053I2 (es)
GE (1) GEP20053658B (es)
HK (1) HK1048126B (es)
HU (2) HU228137B1 (es)
IL (1) IL152315A (es)
LT (1) LT5133B (es)
LU (1) LU91902I2 (es)
LV (1) LV12994B (es)
MX (1) MXPA02011534A (es)
MY (1) MY136113A (es)
NO (2) NO330797B1 (es)
PE (1) PE20011338A1 (es)
PL (1) PL206267B1 (es)
PT (1) PT1248802E (es)
RU (1) RU2283847C2 (es)
SI (1) SI1248802T1 (es)
SK (1) SK288131B6 (es)
TR (1) TR200402703T4 (es)
TW (2) TWI319405B (es)
UA (1) UA87432C2 (es)
UY (1) UY26723A1 (es)
WO (1) WO2001092337A2 (es)
ZA (1) ZA200208944B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
HRP20030071B1 (hr) * 2000-07-03 2014-01-03 Bristol-Myers Squibb Company Postupci za lijeäśenje reumatskih bolesti uporabom topljivih ctla4 mutantnih molekula
MXPA03010568A (es) 2001-05-23 2005-03-07 Squibb Bristol Myers Co Metodos para proteger trasplantes alogenicos de celulas de isletas usando moleculas mutantes ctla4 solubles.
CA2482042A1 (en) * 2002-04-19 2003-10-30 Bristol-Myers Squibb Company Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid
DE10232697A1 (de) * 2002-07-15 2004-02-05 Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen
DE60335024D1 (de) * 2002-12-23 2010-12-30 Bristol Myers Squibb Co Produktqualitätsverbesserung in säugerzellkulturverfahrenzur proteinproduktion
JP4541157B2 (ja) * 2002-12-23 2010-09-08 ブリストル−マイヤーズ スクイブ カンパニー タンパク質を製造するための哺乳類細胞培養法
MXPA05007019A (es) 2002-12-30 2005-08-18 Amgen Inc Terapia de combinacion con factores co-estimuladores.
CA2543484C (en) 2003-10-27 2014-02-04 Amgen Inc. Modulation of immune response to an immunogen with ctla-4 and tnfbp
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
AU2006330922B2 (en) 2005-12-20 2012-07-26 Bristol-Myers Squibb Company Compositions and methods for producing a composition
US7510844B2 (en) 2006-01-24 2009-03-31 Bristol-Myers Squibb Company CD86 and CD80 receptor competition assays
WO2008005290A2 (en) 2006-06-29 2008-01-10 The Trustees Of Columbia University In The City Of New York Methods for testing anti-thrombotic agents
GB0620934D0 (en) 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
KR101546441B1 (ko) 2006-12-20 2015-08-24 엠엠알글로벌, 인코포레이티드 항체 및 이들의 제조 및 사용 방법
CN101998965B (zh) 2007-11-01 2014-03-12 安斯泰来制药有限公司 免疫抑制性多肽与核酸
BRPI0920749A8 (pt) * 2008-10-02 2017-12-12 Emergent Product Dev Seattle Proteínas de ligação de antagonista multialvo cd86
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
US8642557B2 (en) 2010-03-12 2014-02-04 Abbvie Biotherapeutics Inc. CTLA4 proteins and their uses
JP2014506482A (ja) 2011-02-23 2014-03-17 アムジエン・インコーポレーテツド Ｕｖｃ露光のための細胞培養培地およびそれに関連した方法
WO2013010537A1 (en) 2011-07-20 2013-01-24 Aarhus Universitet Method of treating morphea
US9758566B2 (en) 2012-03-29 2017-09-12 The General Hospital Corporation Recombinant cytotoxic T-lymphocyte-associated protein 4 (CTLA4)
KR102133060B1 (ko) 2012-05-11 2020-07-10 메디뮨 리미티드 Ｃｔｌａ－４ 변이체
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
WO2014004857A1 (en) * 2012-06-27 2014-01-03 Orban Biotech Llc Ctla4 fusion proteins for the treatment of diabetes
US20140112958A1 (en) 2012-10-24 2014-04-24 Mwm Biomodels Gmbh Pancreatic islets of transgenic LEA29Y animals for treating diabetes
CN104740608A (zh) * 2013-12-30 2015-07-01 上海中信国健药业股份有限公司 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途
AU2014376225C1 (en) 2014-01-13 2025-06-05 Amgen Inc. Regulating ornithine metabolism to manipulate the high mannose glycoform content of recombinant proteins
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
CN106687575B (zh) 2014-06-04 2021-04-30 美国安进公司 用于收获哺乳动物细胞培养物的方法
SI3227454T1 (sl) 2014-12-01 2020-06-30 Amgen Inc. Postopek za manipuliranje ravni vsebnosti glikana glikoproteina
WO2016130734A1 (en) 2015-02-11 2016-08-18 Bristol-Myers Squibb Company Use of phenolic antioxidants in cell culture for the production of proteins
EP3283508B1 (en) 2015-04-17 2021-03-17 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
CA2997947A1 (en) 2015-09-09 2017-03-16 The Trustees Of Columbia University In The City Of New York Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
JP2018536404A (ja) 2015-11-09 2018-12-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｈｏ細胞において産生したポリペプチドの品質特性を操作する方法
DK3515489T3 (da) 2016-09-19 2026-01-26 Oncoc4 Inc Cd80- og cd86-bindende proteinsammensætinger og deres anvendelse
CN107987153A (zh) * 2016-10-27 2018-05-04 广东香雪精准医疗技术有限公司 高亲和力的可溶性pd-1分子
US12058986B2 (en) 2017-04-20 2024-08-13 Egenesis, Inc. Method for generating a genetically modified pig with inactivated porcine endogenous retrovirus (PERV) elements
JP7749319B2 (ja) 2017-10-10 2025-10-06 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用
BR112020013236A2 (pt) 2018-01-03 2020-12-01 Alpine Immune Sciences, Inc. proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso
CN109453383A (zh) * 2018-11-12 2019-03-12 陈慧慧 免疫检查点的抑制剂在制备治疗青光眼及其他眼部免疫损伤机制相关疾病药物中的应用
EP3887394A2 (en) 2018-11-30 2021-10-06 Alpine Immune Sciences, Inc. Cd86 variant immunomodulatory proteins and uses thereof
JP2022545917A (ja) 2019-08-27 2022-11-01 トニックス ファーマ リミテッド 修飾ｔｆｆ２ポリペプチド
EP3931303A1 (en) 2019-12-06 2022-01-05 Regeneron Pharmaceuticals, Inc. Anti-vegf protein compositions and methods for producing the same
WO2021226444A2 (en) 2020-05-08 2021-11-11 Regeneron Pharmaceuticals, Inc. Vegf traps and mini-traps and methods for treating ocular disorders and cancer
BR112022024135A2 (pt) 2020-06-18 2022-12-27 Regeneron Pharma Metodologia de peptídeo pesado para medir com precisão lisina c-terminal não processada
CA3189533A1 (en) 2020-07-28 2022-02-03 Seagen Inc. Methods and systems for producing polypeptides
CN118647416A (zh) 2021-12-16 2024-09-13 百时美施贵宝公司 用于病毒灭活的洗涤剂
AU2023228815A1 (en) 2022-03-02 2024-09-12 Regeneron Pharmaceuticals, Inc. Manufacturing process for high titer antibody

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
KR100238712B1 (ko) * 1991-06-27 2000-01-15 스티븐 비. 데이비스 씨티엘에이4 수용체,그를 함유한 연합단백질 및 그의 용도
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
GB9809280D0 (en) * 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
CA2346496A1 (en) * 1998-10-07 2000-04-13 Millennium Pharmaceuticals, Inc. Novel th2-specific molecules and uses thereof
HRP20030071B1 (hr) * 2000-07-03 2014-01-03 Bristol-Myers Squibb Company Postupci za lijeäśenje reumatskih bolesti uporabom topljivih ctla4 mutantnih molekula

Also Published As

Publication number Publication date
NO20025656L (no) 2002-11-25
EP1248802B1 (en) 2004-07-14
ES2225549T3 (es) 2005-03-16
LT2002114A (en) 2003-12-29
PE20011338A1 (es) 2002-01-13
RU2283847C2 (ru) 2006-09-20
EP1536234A2 (en) 2005-06-01
KR100889887B1 (ko) 2009-03-24
ES2571852T3 (es) 2016-05-27
CN1309735C (zh) 2007-04-11
WO2001092337A3 (en) 2002-05-10
DE60104282T2 (de) 2005-10-13
TWI319405B (en) 2010-01-11
KR100895134B1 (ko) 2009-05-04
EE05557B1 (et) 2012-08-15
JP4328525B2 (ja) 2009-09-09
SI1248802T1 (en) 2005-02-28
FR11C0053I2 (fr) 2013-01-11
CY2011019I1 (el) 2016-12-14
AU6346601A (en) 2001-12-11
NO20025656D0 (no) 2002-11-25
HK1048126A1 (en) 2003-03-21
BRPI0111191B1 (pt) 2019-12-31
LT5133B (lt) 2004-05-25
NO2011027I2 (es) 2011-12-15
ATE271066T1 (de) 2004-07-15
UA87432C2 (uk) 2009-07-27
CN101255192A (zh) 2008-09-03
NO2011027I1 (no) 2012-01-09
MY136113A (en) 2008-08-29
LV12994B (en) 2003-08-20
IL152315A (en) 2010-04-15
CN1441810A (zh) 2003-09-10
CA2409748C (en) 2008-09-16
ZA200208944B (en) 2004-02-13
EE201100050A (et) 2011-10-17
KR20030009502A (ko) 2003-01-29
BE2011C041I2 (es) 2020-08-20
PL206267B1 (pl) 2010-07-30
HU228137B1 (en) 2012-12-28
SK288131B6 (sk) 2013-10-02
DK1248802T3 (da) 2004-11-15
BRPI0111191B8 (pt) 2021-05-25
PT1248802E (pt) 2004-11-30
CZ304451B6 (cs) 2014-05-14
AU2001263466C1 (en) 2006-10-26
CZ20023892A3 (cs) 2003-09-17
MXPA02011534A (es) 2004-08-12
AU2001263466B2 (en) 2006-04-27
EP1536234B1 (en) 2016-03-16
DE60104282D1 (de) 2004-08-19
EE05458B1 (et) 2011-08-15
TWI314933B (en) 2009-09-21
AR031699A1 (es) 2003-10-01
CA2409748A1 (en) 2001-12-06
EP3029062A1 (en) 2016-06-08
IL152315A0 (en) 2003-05-29
BR0111191A (pt) 2004-07-06
KR20070094019A (ko) 2007-09-19
LU91902I2 (fr) 2012-01-16
DE122011100063I1 (de) 2012-06-14
TR200402703T4 (tr) 2004-11-22
GEP20053658B (en) 2005-11-10
HUP0302201A3 (en) 2010-01-28
EE200200659A (et) 2004-06-15
HUS1300012I1 (hu) 2016-08-29
HK1048126B (en) 2005-03-04
NO330797B1 (no) 2011-07-18
EG24459A (en) 2009-07-16
EP1536234A3 (en) 2009-06-03
EP1248802B9 (en) 2005-05-11
EP1248802A2 (en) 2002-10-16
JP2004511213A (ja) 2004-04-15
UY26723A1 (es) 2001-12-28
FR11C0053I1 (es) 2012-01-13
CY1117625T1 (el) 2017-04-26
HK1071931A1 (en) 2005-08-05
HUP0302201A2 (hu) 2003-10-28
PL366231A1 (en) 2005-01-24
WO2001092337A2 (en) 2001-12-06
SK15702002A3 (sk) 2004-01-08
TW200906857A (en) 2009-02-16
CY2011019I2 (el) 2016-12-14

Similar Documents

Publication Publication Date Title
ECSP024365A (es) Moleculas mutantes solubles ctla4 y sus aplicaciones
CY1106532T1 (el) Ετερολογος εκφραση των πρωτεϊνων της neisseria
DE60131021D1 (de) Klebstoffzusammensetzungen mit selbstorganisierenden molekülen, klebstoffe, gegenstände und verfahren
CY1114626T1 (el) Μεθοδοι κυκλοπολυαιθυλενογλυκολιωσης και πρωτεϊνες/πεπτιδια που παραγονται με αυτες τις μεθοδους
CY1109649T1 (el) Αντιγονα και συνθεσεις απο neisseria
ATE518932T1 (de) Pha-mischungen
CY1106387T1 (el) Τμηματοποιημενα μορια μεταφορεα αντιγονου (ματ-μορια) για τη διαμορφωση ανοσοαποκρισεων, αντιστοιχα δομηματα, μεθοδοι και χρησεις
DE60236861D1 (de) Kombinatorische bibliotheken von monomerdomänen
CY1110530T1 (el) Ανοσοσφαιρινες που εξουδετερωνουν το nogoa για τη θεραπεια νευρολογικων ασθενειων
CY1109068T1 (el) Υποκατεστημενες πυριδινυλαμινες
DK1255826T3 (da) Automatisering af proteindesign for proteinbiblioteker
CY1105194T1 (el) Φωσφονικα παραγωγα γλυκοπεπτιδιων
NO20044039L (no) Konjugatorer av terapeutiske eller cytotoksiske midler og biologisk aktive peptider.
DE60113393D1 (de) Klebstoffzusammensetzungen aus pflanzlichem protein
CY1107759T1 (el) Λυοφιλισμενη συνταγοποιηση που περιλαμβανει ολανζαπινη
GT200300295A (es) Formas de dosificacion que comprenden un inhibidor de la ptec y un inhibidor de la hmg-coa-reductasa
WO2003025119A3 (en) Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies
CY1105009T1 (el) Συνθεση καχαλαλιδης f
ATE457352T1 (de) Subtilisin-carlsberg-proteine mit verminderter immunogenität
PA8508301A1 (es) Inhibidores de la proteina c del procolageno
CY1110718T1 (el) Ανοσογονες λιποσωμικες συνθεσεις
ATE315380T1 (de) Epothilon zusammensetzungen
GB2375112A (en) Combinatorial protein domains
CY1106754T1 (el) Σκευασματα τιμπολονης
BR0116614A (pt) Composições de polìmero biodegradáveis de resposta à água e método de fabricação das mesmas